IM Cannabis (IMCC) Restructuring Costs (2022 - 2023)
IM Cannabis (IMCC) recorded quarterly Restructuring Costs of $248647.1 in Q2 2023, up 18.78% quarter-over-quarter from $209334.1 in Q1 2023, and down 50.16% on a YoY basis from $498840.7 in Q2 2022.
IM Cannabis (IMCC) Restructuring Costs (2022 - 2023) Analysis & Trends
IM Cannabis' Restructuring Costs history runs 2 years deep, the most recent figure standing at $248647.1 for Q2 2023.
- In Q2 2023, Restructuring Costs fell 50.16% year-over-year to $248647.1; the TTM figure through Jun 2024 stood at $248647.1 (up 108.33% YoY), while the FY2023 annual figure was $457299.6, down 86.44% from the prior year.
- Restructuring Costs was $248647.1 for Q2 2023 at IM Cannabis, up from $209334.1 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $3.0 million in Q1 2022 to a low of -$3.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | IM Cannabis | 57,090.22 | -728,264.31 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 248,647.12 |
| Mar 31, 2023 | 209,334.07 |
| Dec 31, 2022 | -3.23 Mn |
| Sep 30, 2022 | -209,321.72 |
| Jun 30, 2022 | 498,840.66 |
| Mar 31, 2022 | 2.96 Mn |